443 related articles for article (PubMed ID: 38111008)
1. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
2. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
Yuan J; Ng WH; Yap J; Chia B; Huang X; Wang M; Hu J
J Biol Chem; 2018 Sep; 293(37):14276-14284. PubMed ID: 30030377
[TBL] [Abstract][Full Text] [Related]
3. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
[TBL] [Abstract][Full Text] [Related]
4. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
5. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP; Marais R
Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
[TBL] [Abstract][Full Text] [Related]
7. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
8. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
9. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
10. CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
Venkatanarayan A; Liang J; Yen I; Shanahan F; Haley B; Phu L; Verschueren E; Hinkle TB; Kan D; Segal E; Long JE; Lima T; Liau NPD; Sudhamsu J; Li J; Klijn C; Piskol R; Junttila MR; Shaw AS; Merchant M; Chang MT; Kirkpatrick DS; Malek S
Cell Rep; 2022 Feb; 38(6):110351. PubMed ID: 35139374
[TBL] [Abstract][Full Text] [Related]
11. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
12. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
13. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
[TBL] [Abstract][Full Text] [Related]
14. Raf inhibitors target ras spatiotemporal dynamics.
Cho KJ; Kasai RS; Park JH; Chigurupati S; Heidorn SJ; van der Hoeven D; Plowman SJ; Kusumi A; Marais R; Hancock JF
Curr Biol; 2012 Jun; 22(11):945-55. PubMed ID: 22560614
[TBL] [Abstract][Full Text] [Related]
15. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
17. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.
Riaud M; Maxwell J; Soria-Bretones I; Dankner M; Li M; Rose AAN
Nat Rev Cancer; 2024 Feb; 24(2):105-122. PubMed ID: 38195917
[TBL] [Abstract][Full Text] [Related]
18. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
20. A MEK-independent role for CRAF in mitosis and tumor progression.
Mielgo A; Seguin L; Huang M; Camargo MF; Anand S; Franovic A; Weis SM; Advani SJ; Murphy EA; Cheresh DA
Nat Med; 2011 Nov; 17(12):1641-5. PubMed ID: 22081024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
